Skip to main content
. 2021 Mar 26;4(2):765–779. doi: 10.1021/acsptsci.0c00214

Figure 6.

Figure 6

WOBE437 as a disease-modifying agent in EAE female C57BL/6 mice. (A) Time course of clinical score from day 0 to day 20; onset is represented at day 1 (red line). The beginning of administration is represented with a blue line. (B) AUC and (C) maximal clinical score observed from the time course of disease severity from day 4 to day 20. (D) Time course of body weight change from day −10 to day 20; onset is represented at day 1. The beginning of administration is marked with a blue line. Administration of vehicle (DMSO, n = 18) or WOBE437 (10 mg/kg, n = 14) was started after disease onset, i.e., when the mouse showed a clinical score 2 or up to 4 days after onset; injections (20 μL) were done i.p. once per day during 15 days. Data show (A, D) mean ± SEM; (B) median, percentile 25, percentile 75, minimum, and maximum; or (C) cumulative frequency. (A–D) Data show the summary of two different cohorts; only mice showing symptoms were included in the study. Statistical differences were determined using (A, D) multiple t-test corrected for multiple comparison with the Holm-Sidak method; (B) Mann–Whitney test; or (C) chi-squared test and Fisher’s exact test. *, p < 0.05 compared to vehicle group.